DEXCOM INC (DXCM)

DexCom, Inc. is a medical device company focused on designing, developing, and commercializing continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health for patients, caregivers, and clinicians globally. The company received its first FDA approval and commercialized its first product in 2006, and has since evolved its product line to include the Dexcom G7 (launched 2023) and the extended-wear G7 15 Day system (launched late 2025), both classified as Class II integrated CGM (iCGM) devices under FDA special controls. In August 2024, DexCom launched Stelo, the first over-the-counter glucose biosensor in the U.S., targeting adults with prediabetes and non-insulin-using Type 2 diabetes, expanding its addressable market beyond insulin-dependent patients.

The G7 and G7 15 Day systems offer improved accuracy (with the G7 15 Day achieving a MARD of 8.0%), smaller and more discreet wearable design, faster warm-up times, predictive low glucose alerts, and integration with mobile devices, insulin pumps, smart pens, and wearables such as Apple Watch and Garmin devices. The company also offers Dexcom ONE and ONE+ systems internationally, and remote monitoring capabilities through Dexcom Share and Follow apps. DexCom has established data and insulin delivery collaborations with multiple partners to integrate its CGM technology into insulin pump and pen systems, and continues to pursue partnerships supporting Type 2 diabetes management and metabolic health monitoring.

The company operates a direct sales force and distribution network across North America and international markets including Europe, Asia Pacific, Latin America, Africa, and the Middle East, complemented by direct-to-consumer marketing initiatives. Its addressable market includes an estimated 38.4 million people with diabetes in the U.S. and 589 million adults globally as of 2024, with projections reaching 853 million by 2050 according to the International Diabetes Federation. DexCom faces intense competition from major players including Abbott Laboratories (Libre family), Medtronic/MiniMed (Guardian Connect, Simplera), Roche Diabetes Care, LifeScan, and Ascensia Diabetes Care, as well as emerging general wellness device makers.

The company's strategy centers on maintaining technology leadership in CGM, expanding indications and patient populations (including pregnancy, obesity, prediabetes, and hospital settings), securing broad insurance coverage and reimbursement, and leveraging cloud-based data platforms and machine learning to generate actionable health insights for users and healthcare providers.